These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33030198)

  • 1. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Taveepanich S; Chayajarus K; Kamsri P; Punkvang A; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2024 Aug; 64(15):5991-6002. PubMed ID: 38993154
    [No Abstract]   [Full Text] [Related]  

  • 4. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.
    Chaudhari K; Surana S; Jain P; Patel HM
    Eur J Med Chem; 2016 Nov; 124():160-185. PubMed ID: 27569197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anti-tubercular and antibacterial based benzosuberone-thiazole moieties: Synthesis, molecular docking analysis, DNA gyrase supercoiling and ATPase activity.
    Omar MA; Masaret GS; Abbas EMH; Abdel-Aziz MM; Harras MF; Farghaly TA
    Bioorg Chem; 2020 Nov; 104():104316. PubMed ID: 33022549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM
    J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
    Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.
    Medapi B; Suryadevara P; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Eur J Med Chem; 2015 Oct; 103():1-16. PubMed ID: 26318054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.
    Jeankumar VU; Renuka J; Santosh P; Soni V; Sridevi JP; Suryadevara P; Yogeeswari P; Sriram D
    Eur J Med Chem; 2013; 70():143-53. PubMed ID: 24148991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Potent DNA Gyrase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria.
    Sterle M; Habjan E; Piga M; Peršolja P; Durcik M; Dernovšek J; Szili P; Czikkely MS; Zidar N; Janez I; Pal C; Accetto T; Pardo LA; Kikelj D; Peterlin Mašič L; Tomašič T; Bitter W; Cotman AE; Speer A; Zega A
    Eur J Med Chem; 2024 Oct; 276():116693. PubMed ID: 39053193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel thiomorpholine tethered isatin hydrazones as potential inhibitors of resistant Mycobacterium tuberculosis.
    Karunanidhi S; Chandrasekaran B; Karpoormath R; Patel HM; Kayamba F; Merugu SR; Kumar V; Dhawan S; Kushwaha B; Mahlalela MC
    Bioorg Chem; 2021 Oct; 115():105133. PubMed ID: 34329993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
    Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Dec; 113():43-54. PubMed ID: 30514513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
    Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
    J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.